查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1397030

全球核酸增幅檢查（NAAT）市場：按技術、應用和最終用戶：機會分析和產業預測（2023-2032）

Nucleic Acid Amplification Testing Market By Technology (Polymerase Chain Reaction Tests, Isothermal Nucleic Acid Amplification Technology Tests), By Application, By End-user : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 272 Pages | 商品交期: 2-3個工作天內

價格

預計2022年全球核酸增幅檢查（NAAT）市場規模將達46億美元，2023年至2032年年複合成長率為6.6%，2032年將達91億美元。核酸增幅檢查，也稱為 NAAT，是一種用於識別病毒感染的實驗室測試。

這些測試用於檢測測試樣本中的少量 DNA 或 RNA，從而檢測血液或尿液樣本中的細菌或病毒。核酸增幅檢查的一大優點是可以從少量的檢測檢體中檢測到目標物質。此方法使用聚合酶鍊式反應 (PCR)、鏈置換測定 (SDA) 或轉錄介導測定 (TMA) 來擴增 DNA 或 RNA 序列。

核酸增幅檢查(NAAT) 透過提取少量 DNA 或 RNA 並進行多次擴增，無需培養即可檢體中的微量細菌。這些方法對於罕見或難以使用傳統技術培養和識別的細菌特別有用。核酸增幅檢查用於檢測定性和定量參數，用於診斷感染疾病、丙型肝炎、巨細胞病毒病毒、人類T細胞淋巴細胞病毒、呼吸道病毒感染疾病、性行為感染等傳染病。由於這些感染疾病的數量不斷增加，對核酸增幅檢查的需求不斷增加，推動了全球市場的成長。

目錄

第1章簡介

第 2 章執行摘要

第3章市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
      • 對先進診斷技術的需求快速成長
      • 感染疾病增加
      • 癌症患者急劇增加
    • 抑制因素
      • 對先進診斷技術缺乏認知
      • 缺乏熟練的高級診斷測試人力資源
    • 機會
      • 對現場檢測的認知和需求不斷成長

第4章核酸增幅檢查（NAAT）市場：依技術分類

  • 概述
  • 聚合酶連鎖反應（PCR）測試
  • 恒溫核酸增幅技術（INAAT）測試

第5章核酸增幅檢查（NAAT）市場：依應用分類

  • 概述
  • 傳染病檢查
  • 腫瘤檢查
  • 其他

第6章核酸增幅檢查（NAAT）市場：依最終用戶分類

  • 概述
  • 院內實驗室
  • 中心實驗室、參考文獻實驗室、獨立實驗室
  • 其他

第7章核酸增幅檢查（NAAT）市場：依地區

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 拉丁美洲/中東/非洲
    • 巴西
    • 沙烏地阿拉伯
    • 南非
    • 其他

第8章競爭形勢

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭儀表板
  • 競爭熱圖
  • 主要企業定位（2022年）

第9章 公司簡介

  • Hologic, Inc.
  • New England Biolabs.
  • Grifols, SA
  • BioMerieux SA
  • Illumina Inc.
  • Abbott Laboratories
  • Perkin Elmer Inc
  • F. Hoffmann-La Roche Ltd.
  • Eiken Chemical Co., Ltd.
  • Siemens AG
Product Code: A180240

The nucleic acid amplification testing market was valued at $4.6 billion in 2022 and is estimated to reach $9.1 billion by 2032, exhibiting a CAGR of 6.6% from 2023 to 2032. Nucleic acid amplification testing, also known as NAAT, is a type of laboratory testing used for identification of viral infections. These tests are used for the detection of small amounts of DNA or RNA in the test sample and thus, are used for detection of bacteria or viruses in the blood or urine sample. The material of interest be detected in a small amount of test samples which proves to be the major advantage of nucleic acid amplification testing. The method involves amplification of DNA or RNA sequences using a polymerase chain reaction (PCR), strand displacement assay (SDA), or transcription-mediated assay (TMA).

Nucleic acid amplification testing (NAAT) identifies minute quantities of an organism in a specimen without the requirement for culture by taking small quantities of DNA or RNA and multiplying it many times. These methods are especially helpful for organisms that are scarce or difficult to cultivate or identify using conventional techniques. Nucleic acid amplification testing is used for detection of both qualitative and quantitative parameters for diagnosis of infections such as hepatitis B, hepatitis C, cytomegalovirus, human T-cell lymphotropic virus, respiratory virus infections, and sexually transmitted infections and others. As the incidences of these infections are on the rise, there is an increasing demand for the nucleic acid amplification testing which boosts market growth globally.

In addition, surge in demand for rapid diagnostic testing and increase in R&D activities to develop advance diagnostic techniques are the major factors driving the growth of the nucleic acid amplification testing market. Key players in the market invest on a large scale to develop new diagnostic tests that are highly precise and require less time as compared to traditional methods.

However, lack of skilled laboratory personnels and limited awareness among the people in low- and middle-income countries are anticipated to hamper the market growth. As people in the underdeveloped countries have limited awareness, the diseases and infections go undiagnosed, thereby acting as a restraint to market growth.

On the other hand, a rise in investment by the key players is anticipated to boost the market growth in the coming years. The key players in the market are investing on a large scale to innovate and develop new diagnostic procedures that are efficient and require less time as compared to the traditional methods. As newer tests are developed, they are expected to boost market growth during the forecast period.

The nucleic acid amplification testing market is segmented on the basis of technology, application, end user, and region. By technology, the market is segmented into polymerase chain reaction (PCR) tests, and isothermal nucleic acid amplification technology (INAAT) test. The INAAT segment is further divided into loop mediated isothermal amplification (LAMP), transcription mediated amplification (TMA), nucleic acid sequence based amplification (NASBA), helicase dependent amplification (HDA), rolling circle amplification (RCA) and others. On the basis of application, the market is categorized into infectious disease testing, oncology testing and other. On the basis of end user, the market is divided into hospitals-based laboratories, central, reference and standalone laboratories, and others.

By region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA). Major players that operate in the market include Hologic, Inc., Grifols, S.A., BioMerieux SA, Illumina Inc., Abbott Laboratories, Perkin Elmer Inc, F. Hoffmann-La Roche Ltd., Siemens AG, Eiken Chemical Co., Ltd. and New England Biolabs.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the nucleic acid amplification testing market analysis from 2022 to 2032 to identify the prevailing nucleic acid amplification testing market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the nucleic acid amplification testing market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global nucleic acid amplification testing market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By End-user

  • Hospital Based Laboratories
  • Central, Reference and Standalone Laboratories
  • Others

By Technology

  • Polymerase Chain Reaction (PCR) Tests
  • Isothermal Nucleic Acid Amplification Technology (INAAT) Tests
    • Type
    • Loop mediated isothermal amplification (LAMP)
    • Transcription mediated amplification (TMA)
    • Nucleic acid sequence based amplification (NASBA)
    • Helicase dependent amplification (HDA)
    • Rolling circle amplification (RCA)
    • Others

By Application

  • Infectious Disease Testing
  • Oncology Testing
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Grifols, S.A.
    • Hologic, Inc.
    • Illumina Inc.
    • F. Hoffmann-La Roche Ltd.
    • Eiken Chemical Co., Ltd.
    • BioMerieux SA
    • Abbott Laboratories
    • Perkin Elmer Inc
    • Siemens AG
    • New England Biolabs.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate intensity of rivalry
    • 3.3.5. High bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Surge in demand for advanced diagnostic techniques
      • 3.4.1.2. Rise in incidences of infectious diseases
      • 3.4.1.3. Surge in prevalence of cancer cases
    • 3.4.2. Restraints
      • 3.4.2.1. Lack of awareness regarding advanced diagnostic techniques
      • 3.4.2.2. Lack of skilled personnel for advanced diagnostic testing
    • 3.4.3. Opportunities
      • 3.4.3.1. Rising awareness and demand for point of care testing

CHAPTER 4: NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY TECHNOLOGY

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Polymerase Chain Reaction (PCR) Tests
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Isothermal Nucleic Acid Amplification Technology (INAAT) Tests
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
    • 4.3.4. Isothermal Nucleic Acid Amplification Technology (INAAT) Tests Nucleic Acid Amplification Testing Market by Type

CHAPTER 5: NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY APPLICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Infectious Disease Testing
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Oncology Testing
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Others
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY END-USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Based Laboratories
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Central, Reference and Standalone Laboratories
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Others
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Technology
    • 7.2.3. Market size and forecast, by Application
    • 7.2.4. Market size and forecast, by End-user
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Technology
      • 7.2.5.1.2. Market size and forecast, by Application
      • 7.2.5.1.3. Market size and forecast, by End-user
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Technology
      • 7.2.5.2.2. Market size and forecast, by Application
      • 7.2.5.2.3. Market size and forecast, by End-user
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Technology
      • 7.2.5.3.2. Market size and forecast, by Application
      • 7.2.5.3.3. Market size and forecast, by End-user
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Technology
    • 7.3.3. Market size and forecast, by Application
    • 7.3.4. Market size and forecast, by End-user
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Technology
      • 7.3.5.1.2. Market size and forecast, by Application
      • 7.3.5.1.3. Market size and forecast, by End-user
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Technology
      • 7.3.5.2.2. Market size and forecast, by Application
      • 7.3.5.2.3. Market size and forecast, by End-user
      • 7.3.5.3. UK
      • 7.3.5.3.1. Market size and forecast, by Technology
      • 7.3.5.3.2. Market size and forecast, by Application
      • 7.3.5.3.3. Market size and forecast, by End-user
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Technology
      • 7.3.5.4.2. Market size and forecast, by Application
      • 7.3.5.4.3. Market size and forecast, by End-user
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Technology
      • 7.3.5.5.2. Market size and forecast, by Application
      • 7.3.5.5.3. Market size and forecast, by End-user
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Technology
      • 7.3.5.6.2. Market size and forecast, by Application
      • 7.3.5.6.3. Market size and forecast, by End-user
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Technology
    • 7.4.3. Market size and forecast, by Application
    • 7.4.4. Market size and forecast, by End-user
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Technology
      • 7.4.5.1.2. Market size and forecast, by Application
      • 7.4.5.1.3. Market size and forecast, by End-user
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Technology
      • 7.4.5.2.2. Market size and forecast, by Application
      • 7.4.5.2.3. Market size and forecast, by End-user
      • 7.4.5.3. India
      • 7.4.5.3.1. Market size and forecast, by Technology
      • 7.4.5.3.2. Market size and forecast, by Application
      • 7.4.5.3.3. Market size and forecast, by End-user
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Market size and forecast, by Technology
      • 7.4.5.4.2. Market size and forecast, by Application
      • 7.4.5.4.3. Market size and forecast, by End-user
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Technology
      • 7.4.5.5.2. Market size and forecast, by Application
      • 7.4.5.5.3. Market size and forecast, by End-user
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Technology
      • 7.4.5.6.2. Market size and forecast, by Application
      • 7.4.5.6.3. Market size and forecast, by End-user
  • 7.5. LAMEA
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Technology
    • 7.5.3. Market size and forecast, by Application
    • 7.5.4. Market size and forecast, by End-user
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Technology
      • 7.5.5.1.2. Market size and forecast, by Application
      • 7.5.5.1.3. Market size and forecast, by End-user
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Market size and forecast, by Technology
      • 7.5.5.2.2. Market size and forecast, by Application
      • 7.5.5.2.3. Market size and forecast, by End-user
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Market size and forecast, by Technology
      • 7.5.5.3.2. Market size and forecast, by Application
      • 7.5.5.3.3. Market size and forecast, by End-user
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Market size and forecast, by Technology
      • 7.5.5.4.2. Market size and forecast, by Application
      • 7.5.5.4.3. Market size and forecast, by End-user

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Hologic, Inc.
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. New England Biolabs.
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
  • 9.3. Grifols, S.A.
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. BioMerieux SA
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Illumina Inc.
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
  • 9.6. Abbott Laboratories
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. Perkin Elmer Inc
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. F. Hoffmann-La Roche Ltd.
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Eiken Chemical Co., Ltd.
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Siemens AG
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 02. NUCLEIC ACID AMPLIFICATION TESTING MARKET FOR POLYMERASE CHAIN REACTION (PCR) TESTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. NUCLEIC ACID AMPLIFICATION TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT) TESTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. GLOBAL ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT) TESTS NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 06. NUCLEIC ACID AMPLIFICATION TESTING MARKET FOR INFECTIOUS DISEASE TESTING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. NUCLEIC ACID AMPLIFICATION TESTING MARKET FOR ONCOLOGY TESTING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. NUCLEIC ACID AMPLIFICATION TESTING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 10. NUCLEIC ACID AMPLIFICATION TESTING MARKET FOR HOSPITAL BASED LABORATORIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. NUCLEIC ACID AMPLIFICATION TESTING MARKET FOR CENTRAL, REFERENCE AND STANDALONE LABORATORIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. NUCLEIC ACID AMPLIFICATION TESTING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 18. U.S. NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 19. U.S. NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 20. U.S. NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 21. CANADA NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 22. CANADA NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 23. CANADA NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 31. GERMANY NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 33. GERMANY NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 37. UK NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 38. UK NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 39. UK NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 40. ITALY NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 41. ITALY NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 42. ITALY NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 46. REST OF EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 47. REST OF EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 48. REST OF EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 49. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 53. JAPAN NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 54. JAPAN NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 55. JAPAN NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 56. CHINA NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 57. CHINA NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 58. CHINA NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 59. INDIA NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 60. INDIA NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 61. INDIA NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 62. AUSTRALIA NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 63. AUSTRALIA NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 64. AUSTRALIA NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH KOREA NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 71. LAMEA NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 72. LAMEA NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 73. LAMEA NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 74. LAMEA NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 75. BRAZIL NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 76. BRAZIL NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 77. BRAZIL NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 78. SAUDI ARABIA NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 79. SAUDI ARABIA NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 80. SAUDI ARABIA NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 81. SOUTH AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 82. SOUTH AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 83. SOUTH AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 84. REST OF LAMEA NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 85. REST OF LAMEA NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 86. REST OF LAMEA NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 87. HOLOGIC, INC.: KEY EXECUTIVES
  • TABLE 88. HOLOGIC, INC.: COMPANY SNAPSHOT
  • TABLE 89. HOLOGIC, INC.: PRODUCT SEGMENTS
  • TABLE 90. HOLOGIC, INC.: PRODUCT PORTFOLIO
  • TABLE 91. HOLOGIC, INC.: KEY STRATERGIES
  • TABLE 92. NEW ENGLAND BIOLABS.: KEY EXECUTIVES
  • TABLE 93. NEW ENGLAND BIOLABS.: COMPANY SNAPSHOT
  • TABLE 94. NEW ENGLAND BIOLABS.: PRODUCT SEGMENTS
  • TABLE 95. NEW ENGLAND BIOLABS.: PRODUCT PORTFOLIO
  • TABLE 96. GRIFOLS, S.A.: KEY EXECUTIVES
  • TABLE 97. GRIFOLS, S.A.: COMPANY SNAPSHOT
  • TABLE 98. GRIFOLS, S.A.: PRODUCT SEGMENTS
  • TABLE 99. GRIFOLS, S.A.: PRODUCT PORTFOLIO
  • TABLE 100. GRIFOLS, S.A.: KEY STRATERGIES
  • TABLE 101. BIOMERIEUX SA: KEY EXECUTIVES
  • TABLE 102. BIOMERIEUX SA: COMPANY SNAPSHOT
  • TABLE 103. BIOMERIEUX SA: PRODUCT SEGMENTS
  • TABLE 104. BIOMERIEUX SA: PRODUCT PORTFOLIO
  • TABLE 105. BIOMERIEUX SA: KEY STRATERGIES
  • TABLE 106. ILLUMINA INC.: KEY EXECUTIVES
  • TABLE 107. ILLUMINA INC.: COMPANY SNAPSHOT
  • TABLE 108. ILLUMINA INC.: PRODUCT SEGMENTS
  • TABLE 109. ILLUMINA INC.: PRODUCT PORTFOLIO
  • TABLE 110. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 111. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 112. ABBOTT LABORATORIES: PRODUCT SEGMENTS
  • TABLE 113. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 114. PERKIN ELMER INC: KEY EXECUTIVES
  • TABLE 115. PERKIN ELMER INC: COMPANY SNAPSHOT
  • TABLE 116. PERKIN ELMER INC: PRODUCT SEGMENTS
  • TABLE 117. PERKIN ELMER INC: PRODUCT PORTFOLIO
  • TABLE 118. PERKIN ELMER INC: KEY STRATERGIES
  • TABLE 119. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 120. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 121. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 122. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 123. EIKEN CHEMICAL CO., LTD.: KEY EXECUTIVES
  • TABLE 124. EIKEN CHEMICAL CO., LTD.: COMPANY SNAPSHOT
  • TABLE 125. EIKEN CHEMICAL CO., LTD.: PRODUCT SEGMENTS
  • TABLE 126. EIKEN CHEMICAL CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 127. SIEMENS AG: KEY EXECUTIVES
  • TABLE 128. SIEMENS AG: COMPANY SNAPSHOT
  • TABLE 129. SIEMENS AG: PRODUCT SEGMENTS
  • TABLE 130. SIEMENS AG: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. NUCLEIC ACID AMPLIFICATION TESTING MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF NUCLEIC ACID AMPLIFICATION TESTING MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN NUCLEIC ACID AMPLIFICATION TESTING MARKET (2022 TO 2032)
  • FIGURE 04. TOP INVESTMENT POCKETS IN NUCLEIC ACID AMPLIFICATION TESTING MARKET (2023-2032)
  • FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 07. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. HIGH BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY TECHNOLOGY, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF NUCLEIC ACID AMPLIFICATION TESTING MARKET FOR POLYMERASE CHAIN REACTION (PCR) TESTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF NUCLEIC ACID AMPLIFICATION TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT) TESTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY APPLICATION, 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF NUCLEIC ACID AMPLIFICATION TESTING MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF NUCLEIC ACID AMPLIFICATION TESTING MARKET FOR ONCOLOGY TESTING, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF NUCLEIC ACID AMPLIFICATION TESTING MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY END-USER, 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF NUCLEIC ACID AMPLIFICATION TESTING MARKET FOR HOSPITAL BASED LABORATORIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF NUCLEIC ACID AMPLIFICATION TESTING MARKET FOR CENTRAL, REFERENCE AND STANDALONE LABORATORIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF NUCLEIC ACID AMPLIFICATION TESTING MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. NUCLEIC ACID AMPLIFICATION TESTING MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 23. U.S. NUCLEIC ACID AMPLIFICATION TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. CANADA NUCLEIC ACID AMPLIFICATION TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. MEXICO NUCLEIC ACID AMPLIFICATION TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. GERMANY NUCLEIC ACID AMPLIFICATION TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. FRANCE NUCLEIC ACID AMPLIFICATION TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. UK NUCLEIC ACID AMPLIFICATION TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. ITALY NUCLEIC ACID AMPLIFICATION TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. SPAIN NUCLEIC ACID AMPLIFICATION TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. REST OF EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. JAPAN NUCLEIC ACID AMPLIFICATION TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. CHINA NUCLEIC ACID AMPLIFICATION TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. INDIA NUCLEIC ACID AMPLIFICATION TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. AUSTRALIA NUCLEIC ACID AMPLIFICATION TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. SOUTH KOREA NUCLEIC ACID AMPLIFICATION TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. REST OF ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. BRAZIL NUCLEIC ACID AMPLIFICATION TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. SAUDI ARABIA NUCLEIC ACID AMPLIFICATION TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. SOUTH AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. REST OF LAMEA NUCLEIC ACID AMPLIFICATION TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
  • FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
  • FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
  • FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 46. COMPETITIVE DASHBOARD
  • FIGURE 47. COMPETITIVE HEATMAP: NUCLEIC ACID AMPLIFICATION TESTING MARKET
  • FIGURE 48. TOP PLAYER POSITIONING, 2022
  • FIGURE 49. HOLOGIC, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 50. HOLOGIC, INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 51. HOLOGIC, INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 52. GRIFOLS, S.A.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 53. GRIFOLS, S.A.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 54. GRIFOLS, S.A.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 55. BIOMERIEUX SA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. BIOMERIEUX SA: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 57. BIOMERIEUX SA: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 58. ILLUMINA INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 59. ILLUMINA INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 60. ILLUMINA INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 61. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 62. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 63. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 64. PERKIN ELMER INC: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 65. PERKIN ELMER INC: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 66. PERKIN ELMER INC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 67. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 68. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 69. SIEMENS AG: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 70. SIEMENS AG: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)
  • FIGURE 71. SIEMENS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 72. SIEMENS AG: REVENUE SHARE BY REGION, 2022 (%)